hrs4r
 I want to donate

XAVIER HERNÁNDEZ YAGÜE

Firma
XAVIER HERNÁNDEZ-YAGÜE
Position
Investigador/a Pre-doctoral – R1
Predoctoral Researchers – R1

Projectes

Codi oficial: VEGF/EGFR Start date:11/06/2022 Data fi: 10/06/2024 Investigador/a principal: XAVIER HERNÁNDEZ YAGÜE Organisme finançador: FUNDACIÓ ACADÈMIA CIÈNCIES MÈDIQUES Ajuda: 6,000 €
Codi oficial: IMPROSA Start date:01/04/2022 Data fi: 30/06/2023 Investigador/a principal: ERNESTO BARZOLA NAVARRO Organisme finançador: F. ASOC. ESP. COLOPROCTOLOGIA Ajuda: 6,600 €

Publicacions

Planellas P, Cornejo L, Rodríguez-Hermosa JI, Maldonado E, Timoteo A, Hernández-Yagüe X, Farrés R, Codina-Cazador A

Is Metformin Associated With Improved Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer?

JOURNAL OF SURGICAL RESEARCH, 2021, 268, 465-473 dx.doi.org/10.1016/j.jss.2021.06.079

Planellas Giné P, Cornejo Fernández L, Salvador Rosés H, Buxó Pujolras M, Farrés Coll R, Hernandez Yague X, Canals Subirats E, Gil Garcia J, Rodríguez Hermosa JI, Codina Cazador A

Delaying surgery by more than 10 weeks after long-course neoadjuvant radiotherapy in locally advanced rectal cancer patients improves pathologic complete response.

Updates in Surgery, 2020, 72, 453-461 dx.doi.org/10.1007/s13304-020-00747-0

Oliveras-Ferraros C, Vazquez-Martin A, Queralt B, Adrados M, Ortiz R, Cufí S, Hernández-Yagüe X, Guardeño R, Báez L, Martin-Castillo B, Pérez-Martínez MC, Lopez-Bonet E, De Llorens R, Bernadó L, Brunet J, Menendez JA

Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.

INTERNATIONAL JOURNAL OF ONCOLOGY, 2011, 39, 1455-1479 dx.doi.org/10.3892/ijo.2011.1155

Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Queralt B, Báez L, Guardeño R, Hernández-Yagüe X, Martin-Castillo B, Brunet J, Menendez JA

Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells.

JOURNAL OF CELLULAR BIOCHEMISTRY, 2011, 112, 10-29 dx.doi.org/10.1002/jcb.22952

Formulari de contacte

About IDIBGI!

menu